Skip to Content

Fulcrum Therapeutics Inc FULC Stock Quote

| Rating as of

Morningstar‘s Stock Analysis FULC

Valuation
Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Key Statistics FULC

Company Profile FULC

Business Description

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. It has developed a proprietary product engine that employs to identify and validate cellular drug targets that can modulate gene expression. Its product candidate, losmapimod, is a small molecule that was developed for the treatment of FSHD, a muscle-wasting disorder that leads to physical impairments and disability.

Contact
26 Landsdowne Street
Cambridge, MA, 02139
T +1 617 651-8851
Industry Biotechnology
Most Recent Earnings Jun 30, 2022
Fiscal Year End Dec 31, 2022
Stock Type Distressed
Employees 104